Evidence map›Paper›PMID 40641819›Full record

ArticleEClinicalMedicine2025

Development and validation of risk stratification and shared decision-making tool for catheter ablation for atrial fibrillation in patients with heart failure: a multicentre cohort study.

Xiaodong Peng, Liu He, Jue Wang, Nan Li, Jing Cui, Shijun Xia, Song Zuo, Chao Jiang, Jinzhu Hu, Kui Hong and 8 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiaodong PengDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Liu HeDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Jue WangDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Nan LiDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Jing CuiDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Shijun XiaDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Song ZuoDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Chao JiangDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Jinzhu HuDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Kui HongDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Zhuheng LiDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Peng ZhangDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Ning ZhouDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Caihua SangDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Deyong LongDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Xin DuDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Jianzeng DongDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.
Changsheng MaDepartment of Cardiology, Beijing AnZhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Office of Beijing Cardiovascular Diseases Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The coexistence of atrial fibrillation (AF) and heart failure (HF) presents a significant challenge in risk evaluation and treatment decision-making. This study aimed to develop a shared decision-making tool that aids in risk stratification and guides radiofrequency catheter ablation (RFCA) decisions for patients with AF and HF. Methods: In this multicentre cohort study, we derived a shared decision-making tool by applying unsupervised clustering and supervised learning models to data from the China-AF registry, collected from 31 hospitals between August 1, 2011, and December 31, 2022. External validation was performed using diverse ethnic populations from the international, multicenter, randomized, open-label CABANA trial. The study included patients with AF and HF and excluded the asymptomatic patients. Association of RFCA with prognostic outcomes were assessed and compared across model-identified risk strata, focusing on composite events (cardiovascular death and stroke), all-cause death, cardiovascular hospitalization, major bleeding, and AF recurrence. This study is registered with the Chinese Clinical Trial Registry, ChiCTR-OCH-13003729. Findings: Among 3122 patients in the derivation cohort (1476 females [47.3%] and 1646 males [52.7%]) and the 778 patients in the validation cohort (345 females [44.3%] and 433 males [55.7%]), the tool identified three clusters based on 25 readily accessible clinical features. Incidence rates (per 100 person-years) of composite events were highest in cluster 1 [7.7 (95% CI, 6.9-8.6)], followed by cluster 2 [6.8 (95% CI, 6.1-7.7)], and lowest in cluster 3 [3.8 (95% CI, 3.4-4.4)] (log-rank Interpretation: This machine learning-based tool shows promise in facilitating shared decision-making for patients with AF and HF by identifying those most likely to benefit from RFCA following risk stratification. However, as the tool was developed based on observational study data, its effectiveness requires further validation in interventional trials and real-world clinical practice. Funding: The National Key Research and Development Program of China, Beijing Hospitals Authority Yangfan Program, Engineering Research Center of Cardiovascular Diagnostic and Therapeutic Technologies and Devices, Ministry of Education and the National Natural Science Foundation of China.

Indexed as

Atrial fibrillationClusteringHeart failureMachine learningRadiofrequency catheter ablationRisk stratification

Identifiers

PMID40641819
PMCPMC12242850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.